60-Day PNS Treatment May Improve Identification of Delayed Responders and Delayed Non-Responders to Neurostimulation for Pain Relief

• DOI: 10.2147/jpr.s349101
• Publication Date: 2022-03-14T06:40:07Z
• Authors: Ramana Naidu; Sean Li; Mehul J Desai; Samir Sheth; Nathan D Crosby; Joseph W Boggs
• Keywords: Neurostimulation; Symptom relief

Conventional neurostimulation typically involves a brief (eg, ≤10-day) trial to assess presumed effectiveness prior permanent implantation. Low conversion rates and high explant due inadequate pain relief highlight the need for improved patient identification strategies. The development of 60-day percutaneous peripheral nerve stimulation (PNS) system enables evaluation outcomes following an extended temporary treatment period up 60 days, that may obviate or validate implant. present study provides first real-world evidence regarding response throughout PNS period.Anonymized data listings were compiled from patients who underwent implantation leads opted-in provide device manufacturer during routine interactions with representatives treatment.Overall, 30% (222/747) early responders (≥50% treatment). Another 31% (231/747) initially presented as non-responders but surpassed 50% by end treatment. Conversely, 32% (239/747) An additional 7% (55/747) fell below period.An extended, help identify delayed responders, providing opportunity sustained improving access effective Compared conventionally short ≤10 longer also reduce identifying unlikely benefit long-term. These scenarios support importance inform stepwise strategies optimize cost-effectiveness.